

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 64717

Title: Management of hepatitis B and C in special population

Reviewer's code: 03478933

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: India

Manuscript submission date: 2021-02-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-11 01:35

Reviewer performed review: 2021-04-11 04:28

Review time: 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

This is a well-written review in terms of current strategy in treatment of HBV/HCV for special populations. As a special population, authors selected patients with CKD, patients in pregnancy, health care workers, connected patients, and immunosuppressed patients. By reading this concise review, readers will find that antiviral interventions have become possible even in special populations that were previously untreated. These information should be helpful for all healthcare professionals to achieve the goal of global elimination of viral hepatitis in the future. Comments; 1 Use of sofosubvir/velpatasvir for patients with renal impairment has been approved many countries, but still off-label in some area. Please note this information in the text. 2 As a special population, children infected with HCV may be included since recent approvals of several DAAs for them. Minor comment Number of reference should be inserted before the period.